LONDON, September 11, 2012 /PRNewswire/ --
A new report by visiongain predicts that the world market for pharmaceutical contract manufacturing will be worth $47.6 billion in 2012. Between 2011 and 2016, the overall market will grow with a compound annual growth rate (CAGR) of over 6%. Demand for outsourcing will increase worldwide, driving revenue growth. Those findings and others appear in Pharmaceutical Contract Manufacturing: World Market Outlook 2012-2022, published in August 2012.
In 2011, active pharmaceutical ingredient (API) manufacturing services formed the largest market sector, accounting for more than two thirds of revenues. APIs will account for the majority of revenues throughout the coming 10 years. Increased demand for generic drugs will drive revenue growth for emerging-market contract manufacturing organisations (CMOs). Highly potent API (HPAPI) manufacturing will drive growth in the US and Europe. Increased outsourcing of finished dosage manufacturing will also stimulate developed-market growth. Development of biologics will increase demand for injectable dosage manufacturing services, including fill-finish and lyophilisation, the report also notes.
Richard Lang, a pharmaceutical industry analyst for visiongain, said: "Difficult economic conditions caused revenue to drop for many leading CMOs in recent years. Among the leading US and European market players, only a few achieved continuous revenue growth between 2009 and 2011. Many are now reporting an increased uptake of services, however. To remain competitive in the future, companies will need to react to trends in drug development. Companies investing in biologics manufacturing capacity will benefit from increased interest in this area."
Visiongain's study forecasts the leading national pharmaceutical contract manufacturing markets in terms of demand. In 2011, the leading national market was the US, accounting for over 40% of demand for outsourced manufacturing. Much of this demand is met by CMOs in the US and EU. However, pharmaceutical companies will increasingly use CMOs in India and China to supply APIs in the coming 10 years. Growth in national pharmaceutical markets in emerging countries will stimulate demand for outsourcing there. This demand will come from multinational companies seeking to enter the market, and domestic drug developers wanting to cut costs.
The updated report provides quantitative and qualitative analysis of the contract manufacturing industry and market. It shows revenue forecasts for leading sectors and national markets and identifies future trends that will affect companies. The work also discusses 20 leading CMOs, including Catalent, Lonza and Patheon.
Pharmaceutical Contract Manufacturing: World Market Outlook 2012-2022 adds to visiongain's portfolio of analytical reports covering pharmaceutical outsourcing and services markets. Visiongain is a business information provider based in London, UK.
For sample pages and further information concerning the Lyophilisation for Pharmaceuticals: Products and Services Market 2012-2022 please visit: http://www.visiongain.com/Report/880/Pharmaceutical-Contract-Manufacturing-World-Market-Outlook-2012-2022
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Companies mentioned in the report include:
Abbott Contract Manufacturing (part of Abbott Laboratories)
Aenova (formerly Dragenopharm Apotheker Püschl and Swiss Caps)
Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
Albany Molecular Research (AMRI)
Ben Venue Laboratories (part of Boehringer Ingelheim)
Cambridge Major Laboratories (CML)
Centocor (now known as Janssen Biologics)
Cobra Biologics Holding
Department of Pharmaceuticals [India]
Dr. Reddy's Laboratories
DSM Sinochem Pharmaceuticals (DSP)
Enobia Pharma (part of Alexion Pharmaceuticals)
European Commission (EC)
European Medicines Agency (EMA)
Evonik Degussa (part of Evonik Industries)
FDA Office of Combination Products (OCP) [US]
Food and Drug Administration (FDA) [US]
Government Accountability Office (GAO) [US]
Hospira One 2 One (part of Hospira)
Human Genome Sciences (part of GSK)
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
Jubilant HollisterStier (part of Jubilant Life Sciences)
Jubilant Life Sciences
Korea Food and Drug Administration (KFDA)
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Nycomed (part of Takeda Pharmaceutical)
Pfizer CentreSource (part of Pfizer)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
R5 (part of Aesica Pharmaceuticals)
RecipharmCobra Biologics (part of Cobra Biologics Holding)
Sigmar Italia (part of Fareva)
State Food and Drug Administration (SFDA) [China]
Sun Capital Partners
SurModics (part of Evonik Industries)
Teva Pharmaceutical Industries
Therapeutic Goods Administration (TGA) [Australia]
Vivante GMP Solutions (part of Lonza)
Wasserburger Arzneimittelwerk (part of Recipharm)
World Health Organization (WHO)
For an executive summary of this report or to order it today please contact:
Email: Sara Peerun on email@example.com
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44(0)207-336-6100